Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Primary Care
  • Patient/Physician Communication
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.